Caris Life Sciences (CAI) Income from Continuing Operations (2024 - 2026)
Caris Life Sciences' (CAI) quarterly Income from Continuing Operations came in at 510000.0 in Q1 2026, up 99.5% year-on-year from 255635.47 in Q1 2025, and down 100.62% quarter-over-quarter from 81957000.0 in Q4 2025.
Caris Life Sciences (CAI) Income from Continuing Operations (2024 - 2026) Analysis & Trends
Caris Life Sciences' Income from Continuing Operations history runs 3 years deep, the most recent figure standing at 510000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 99.5% year-over-year to 510000.0 in Q1 2026; TTM through Mar 2026 was 33982000.0, a 112.43% increase from a year earlier, with the FY2025 full-year figure at 68088000.0, up 75.85% from the prior year.
- Income from Continuing Operations slipped to 510000.0 in Q1 2026 per CAI's latest filing, from 81957000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 81957000.0 in Q4 2025 and bottomed at 102581000.0 in Q1 2025.
- The 3-year median for Income from Continuing Operations is 51566500.0 (2024), against an average of 29932625.0.
- Biggest YoY gain for Income from Continuing Operations was 321.82% in 2025; the steepest drop was 8.47% in 2025.
- Year by year, Income from Continuing Operations stood at 36947000.0 in 2024, then soared by 321.82% to 81957000.0 in 2025, then tumbled by 100.62% to 510000.0 in 2026.
- Per Business Quant, the three latest CAI Income from Continuing Operations figures stand at 510000.0 (Q1 2026), 81957000.0 (Q4 2025), and 24325000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Caris Life Sciences | 4.35 Bn | 3.53 Bn | 214.23 Mn | -510,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -510,000.00 |
| Dec 31, 2025 | 81.96 Mn |
| Sep 30, 2025 | 24.33 Mn |
| Jun 30, 2025 | -71.79 Mn |
| Mar 31, 2025 | -102.58 Mn |
| Dec 31, 2024 | -36.95 Mn |
| Sep 30, 2024 | -67.73 Mn |
| Jun 30, 2024 | -66.19 Mn |